Introduction: a new era in the pharmacotherapy of psychotic disorders.
Breier
A
A
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA. breier_alan@lilly.com
D000208:Acute Disease; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy; D004334:Drug Administration Schedule; D017277:Drug Approval; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine